Anatara Lifesciences (ASX:ANR), a company focused on commercialising innovative products for gut health, has announced the formation of its Product Development Advisory Board.
The Advisory Board consists of five external experts: Dr Rebecca Burgell, Dr Jakob Begun, Professor Barry Campbell, Associate Professor Simon Keely and Professor Peter Gibson.
Professor Gibson will serve as the Chairman.
The company said its new Advisory Board will work closely with the its Board and management as it continues to advance its human gastrointestinal (GI) health program.
The Advisory Board will provide advice on issues relating to Anatara’s research priorities and strategies and its product development programs.
According to company Chair Sue MacLeman, “We feel privileged to have attracted advisors with world-leading experience in gastrointestinal disorders to join Anatara’s inaugural Advisory Board. The group will assist with guiding our scientific programs and will advise on our long-term strategic goals. Their expertise will be valuable as we look toward commercialising our first human product candidate, the Gastrointestinal Reprogramming (GaRP) dietary supplement, and to the further development of our human product pipeline.”
Professor Peter Gibson will assume the role of Chairman of the Advisory Board. He has more than 30 years experience in gastrointestinal health.
“Anatara’s focus on human gastrointestinal disorders is an exciting new development in the growing gut health space. Irritable Bowel Syndrome (IBS) is a chronic condition that affects up to 15% of all Australians at some point in their life,” said Professor Peter Gibson.
“Together with my Advisory Board colleagues, I look forward to assisting Anatara as they develop products to assist with the debilitating symptoms associated with gastrointestinal disorders such as IBS.”
Interim CEO Dr Tracie Ramsdale said, “It is a testament to the potential of Anatara’s human gastrointestinal health program that we have been able to attract such prominent scientists and clinicians to our product development Advisory Board. We continue to focus on the development of our GaRP dietary supplement program, which we hope will serve to greatly assist patient wellbeing for those with gastrointestinal disorders like Inflammatory Bowel Disease and Irritable Bowel Syndrome.”
She continued, “GaRP is being developed to be a multi-component dietary supplement, designed to address the primary underlying factors associated with gastrointestinal disorders, such as inflammation, a dysfunctional microbiome, impaired intestinal barrier function and mucosal damage. The advisory board will meet twice yearly, as well as when needed for specific additional purposes, as we accelerate GaRP’s proof of concept studies and assess other potential product opportunities in gastrointestinal health.”